Scott Rottinghaus
Hoofd Techniek/Wetenschap/O&O bij ENANTA PHARMACEUTICALS, INC.
Vermogen: 353 022 $ op 30-04-2024
Actieve functies van Scott Rottinghaus
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ENANTA PHARMACEUTICALS, INC. | Hoofd Techniek/Wetenschap/O&O | 08-08-2022 | - |
Loopbaan van Scott Rottinghaus
Eerdere bekende functies van Scott Rottinghaus
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | - | - |
Opleiding van Scott Rottinghaus
| Mayo Medical School | Doctorate Degree |
| University of Cambridge | Graduate Degree |
| Kansas State University | Undergraduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 4 |
| 2 | |
| Verenigd Koninkrijk | 2 |
Operationeel
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
Sectoraal
| Consumer Services | 4 |
| Health Technology | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| ENANTA PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
- Beurs
- Insiders
- Scott Rottinghaus
- Ervaring
